| Subtype . | European . | Hispanic . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | |||||||||
| . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . |
| Controls | 1427 | 1 | 3 | reference | reference | 1352 | 3 | 7 | reference | reference | 2779 | 4 | 10 | reference | reference |
| GBM1 | 44 | 2 | 0 | 64.86* (5.77–728.80) | 98.33* (8.06–1200.01) | 43 | 1 | 0 | 10.43* (1.06–102.33) | 9.93+ (0.93–105.68) | 87 | 3 | 0 | 23.85* (5.25–108.19) | 29.30* (5.25–163.4) |
| POL2 | 455 | 0 | 0 | 0 | 1.003 (0.01–93.60) | 332 | 0 | 0 | 0 | 0.58 (0.02–18.09) | 787 | 0 | 0 | 0 | 0.71 (0.05–10.98) |
| AST3 | 329 | 0 | 0 | 0 | 1.54 (0.02–144.82) | 263 | 0 | 0 | 0 | 0.75 (0.02–23.33) | 592 | 0 | 0 | 0 | 0.97 (0.06–15.11) |
| OLG4 | 47 | 0 | 0 | 0 | 13.39 (0.14–1323.29) | 28 | 0 | 0 | 0 | 5.54 (0.17–183.06) | 75 | 0 | 0 | 0 | 7.66 (0.49–118.99) |
| Subtype . | European . | Hispanic . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | |||||||||
| . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . |
| Controls | 1427 | 1 | 3 | reference | reference | 1352 | 3 | 7 | reference | reference | 2779 | 4 | 10 | reference | reference |
| GBM1 | 44 | 2 | 0 | 64.86* (5.77–728.80) | 98.33* (8.06–1200.01) | 43 | 1 | 0 | 10.43* (1.06–102.33) | 9.93+ (0.93–105.68) | 87 | 3 | 0 | 23.85* (5.25–108.19) | 29.30* (5.25–163.4) |
| POL2 | 455 | 0 | 0 | 0 | 1.003 (0.01–93.60) | 332 | 0 | 0 | 0 | 0.58 (0.02–18.09) | 787 | 0 | 0 | 0 | 0.71 (0.05–10.98) |
| AST3 | 329 | 0 | 0 | 0 | 1.54 (0.02–144.82) | 263 | 0 | 0 | 0 | 0.75 (0.02–23.33) | 592 | 0 | 0 | 0 | 0.97 (0.06–15.11) |
| OLG4 | 47 | 0 | 0 | 0 | 13.39 (0.14–1323.29) | 28 | 0 | 0 | 0 | 5.54 (0.17–183.06) | 75 | 0 | 0 | 0 | 7.66 (0.49–118.99) |
1 glioblastoma
2 pilocytic astrocytoma
3 nonpilocytic astrocytoma
4 oligodendroglioma
* P value is significant (P < .05)
+ P value is borderline significant (P < .1)
| Subtype . | European . | Hispanic . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | |||||||||
| . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . |
| Controls | 1427 | 1 | 3 | reference | reference | 1352 | 3 | 7 | reference | reference | 2779 | 4 | 10 | reference | reference |
| GBM1 | 44 | 2 | 0 | 64.86* (5.77–728.80) | 98.33* (8.06–1200.01) | 43 | 1 | 0 | 10.43* (1.06–102.33) | 9.93+ (0.93–105.68) | 87 | 3 | 0 | 23.85* (5.25–108.19) | 29.30* (5.25–163.4) |
| POL2 | 455 | 0 | 0 | 0 | 1.003 (0.01–93.60) | 332 | 0 | 0 | 0 | 0.58 (0.02–18.09) | 787 | 0 | 0 | 0 | 0.71 (0.05–10.98) |
| AST3 | 329 | 0 | 0 | 0 | 1.54 (0.02–144.82) | 263 | 0 | 0 | 0 | 0.75 (0.02–23.33) | 592 | 0 | 0 | 0 | 0.97 (0.06–15.11) |
| OLG4 | 47 | 0 | 0 | 0 | 13.39 (0.14–1323.29) | 28 | 0 | 0 | 0 | 5.54 (0.17–183.06) | 75 | 0 | 0 | 0 | 7.66 (0.49–118.99) |
| Subtype . | European . | Hispanic . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | m1555 Genotype . | Odds Ratio (95%CI) . | |||||||||
| . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . | A . | G . | NA . | Raw . | Adjusted . |
| Controls | 1427 | 1 | 3 | reference | reference | 1352 | 3 | 7 | reference | reference | 2779 | 4 | 10 | reference | reference |
| GBM1 | 44 | 2 | 0 | 64.86* (5.77–728.80) | 98.33* (8.06–1200.01) | 43 | 1 | 0 | 10.43* (1.06–102.33) | 9.93+ (0.93–105.68) | 87 | 3 | 0 | 23.85* (5.25–108.19) | 29.30* (5.25–163.4) |
| POL2 | 455 | 0 | 0 | 0 | 1.003 (0.01–93.60) | 332 | 0 | 0 | 0 | 0.58 (0.02–18.09) | 787 | 0 | 0 | 0 | 0.71 (0.05–10.98) |
| AST3 | 329 | 0 | 0 | 0 | 1.54 (0.02–144.82) | 263 | 0 | 0 | 0 | 0.75 (0.02–23.33) | 592 | 0 | 0 | 0 | 0.97 (0.06–15.11) |
| OLG4 | 47 | 0 | 0 | 0 | 13.39 (0.14–1323.29) | 28 | 0 | 0 | 0 | 5.54 (0.17–183.06) | 75 | 0 | 0 | 0 | 7.66 (0.49–118.99) |
1 glioblastoma
2 pilocytic astrocytoma
3 nonpilocytic astrocytoma
4 oligodendroglioma
* P value is significant (P < .05)
+ P value is borderline significant (P < .1)
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
